BEAC Setup

CCME to begin trading on the NASDAQ on June 3rd

Press Release Source: China MediaExpress Holdings, Inc. On Wednesday May 19, 2010, 8:45 am

FUJIAN, China--(BUSINESS WIRE)--China MediaExpress Holdings, Inc. (NYSE Amex: CCME) (“CME” or “Company”), China’s largest television advertising operator on inter-city and airport express buses, today announced that its common stock has been approved for listing on the NASDAQ Global Select Market.

Effective as of the close of trading on June 2, 2010, the Company’s common stock will cease trading on NYSE AMEX. Upon the opening of trading on June 3, 2010, the Company's shares will commence trading on NASDAQ Global Select Market, under the same ticker symbol "CCME".

Mr. Zheng Cheng, CME’s Founder and CEO, noted, “We believe that NASDAQ represents the best fit for our Company and our shareholders. NASDAQ's market maker structure should lead to increased liquidity, an expansion in our shareholder base and, ultimately, to increased shareholder value. In addition it will provide our investors with the best prices and the fastest execution. As the world's largest electronic stock market, NASDAQ promotes innovation and attracts leading growth companies from a diverse group of sectors. CME is one of the very few Chinese companies to qualify for the NASDAQ Global Select Market, which has the highest initial listing standards of any exchange in the world. Out of 136 China-based companies listed on NASDAQ, only 26 companies such as Baidu, CTrip.com International, Shanda Interactive Entertainment and NetEase.com, fulfill NASDAQ Global Select Market requirements. Within only seven months since CME became a public company in October 2009, we have qualified and are making the decision to move to the NASDAQ Global Select Market. This achievement is an important milestone for our Company and we look to the future with confidence.”

Long and Strong!

Trading ideas for May 17, 2010

MILL (Long Setup)


YGE (Short Setup)

Celsion's Phase III ThermoDox HEAT study Recommended for Continuation by Data Monitoring Committee

"COLUMBIA, Md., May 13 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq:CLSN - News) announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

The DMC for the HEAT study is comprised of an independent group of medical and scientific experts who are responsible for reviewing and evaluating patient safety and efficacy data. The DMC reviews study data at regular intervals with the charter to ensure patient safety and monitor the quality and overall conduct of the study. The study design and statistical plan for the Phase III ThermoDox trial also incorporates a pre-planned interim efficacy analysis by the DMC after patient enrollment is complete, with the intent to stop the study if there is overwhelming evidence of treatment benefit or a low probability of treatment success.

"We are pleased that the DMC has recommended continuation of the study based on its review of all of the available study data," stated Michael H. Tardugno, President and Chief Executive Officer of Celsion. "The DMC's affirmative review of the 12 Japanese patients enrolled to date is a positive step forward, as it confirms Celsion and Yakult's decision to initiate Phase III trials in Japan. The arrangement, to move directly into Phase III trials was based on previous evidence in primary liver cancer patients, may have shortened our timeline for approval in Japan by two years. With recent acceleration in patient recruitment, and the study now almost 60% enrolled, we are optimistic of a timely completion to enrollment."

Celsion's global Phase III ThermoDox study for primary liver cancer plans to enroll 600 patients and is being conducted under a FDA Special Protocol Assessment (SPA). The study is designed to evaluate the efficacy of ThermoDox in combination with radiofrequency ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival. Additional information on the Phase III ThermoDox clinical study may be found at www.clinicaltrials.gov."

LONG AND STRONG!! Accumulated more from last week.

Trading ideas for May 13, 2010

GMO


AUTH

May 12, 2010 watch list update

May 12, 2010 watch list!

GSS VG HOKU GBG SRLS MBTF SURG AAU GSIT AKRX

GLD NEW HIGH

Alert from April 27 Inverse Head and Shoulder breakout.

May 11, 2010 close

@Weeklyta alert on Gold from early April.

VG setup

Alert from @kunal00 this morning from 1.70. Looking for continuation.

MCGI Setup

Still enjoying my break at the moment. I am going to let the dust settle before I start trading like a maniac. So far this is the only breakout setup that is worth a shot IMHO.

BROKEN TAPE

It is going to take a while to fix this tape. However, I am going to take this opportunity to load up cheap shares of $CLSN (One of my buy and hold stocks for 2010). Happy Trading everyone!

ARIA Trade

Been checking in late the past couple of days to avoid the recent downward pressure in the market. Not a bad trade on ARIA today.

ARIA setup

CRXX gap up play wins// overnight hold

Alerted on twitter: Ranked CRXX highest out of the three overnight gap up play.

Overnight hold update:
AKRX SCLN DVAX

Overnight Gap up plays!

$SHIP $CRXX $DVAX

GMO trade

Did a quick scalp on $GMO today.

DAILY


Intraday


Place a stop below $4.18 if you are swinging $GMO.

Fibo is your friend

Trading ideas for May 03, 2010

LONG setup: ENP

ENP


SHORT setup: GROW TNP FUQI

GROW


FUQI


TNP

SPX fibo retracement level.

WOW?



Watch this video for more detail.

IMAX retracement

FRG setup

KERX setup

THC setup

GLD Brokeout above 2010 highs

CHTP setup

ENT setup

UNIS SETUP

Trades of the day

Bought AIG close to the break of $45. (Easy Trade)


Bought 1k CSNT for a test and it spiked 50 cents in less than 40 seconds.

ATHX Setup

CERS setup

ANTF setup update

Alerted ANTF on Monday at $2.10.



Looks toppy here as volume continue to decrease while the stock keeps climbing higher.

HAFC setup

Trading ideas for April 22, 2010

DYAI


ZZ

DCTH Delcath Phase III Trial Results Exceed Primary Endpoint Expectations

CONGRATS TO ALL LONGS!

NEW YORK, April 21 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq:DCTH - News), a development stage, oncology-focused, specialty pharmaceutical and medical device company, announced that its Phase III National Cancer Institute (NCI)-led multi-center clinical trial has successfully met the study's primary endpoint of extended hepatic progression-free survival (hPFS) in patients with melanoma metastases to the liver based on an independently corroborated intent-to-treat analysis. Comparing treatment with the Delcath PHP System™ with melphalan to Best Alternative Care (BAC), based on independent core lab review of patient scans, the statistical analysis revealed that the PHP patients had a statistically significant longer median hPFS of 214 days compared to 70 days in the BAC arm (p=0.001). This reflects a 144-day prolongation of hPFS over that of BAC control arm, with less than half the risk of progression and/or death in the PHP group compared to the BAC group (Hazard Ratio = 0.46).

James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine and a lead Principal Investigator of the Phase III trial, will present full trial data on June 5th at the American Society of Clinical Oncology's (ASCO) 2010 Annual Meeting. The endpoints announced today are results of the independent core lab analysis, which will be submitted to support Delcath's New Drug Application (NDA) for its drug and proprietary treatment system to the U.S. Food and Drug Administration (FDA). Delcath expects to initiate its rolling NDA submission to the FDA within the next 30 days.

"We believe that these data support that the Delcath PHP System may provide a significantly better treatment option for patients suffering from melanoma metastases in the liver," said Eamonn P. Hobbs, President and CEO of Delcath. "With the treatment arm having a median hPFS of more than three-fold that of the control arm, we easily exceeded our expectations of clinical trial success. This is a major step forward in our plan to introduce what we believe is an effective treatment for patients who currently have very few viable options."

YRCW Setup

PIR setup

Trading ideas for April 21, 2010

THC


ISCO

The REED Trade

ANTF setup

Setups looks great today. Bought with stop loss below 1.98. Will add more on $2.20 breakout

Overnight positions Chart setups April 19, 2010

Last Friday, I should not have load up so much overnight positions when market came out with unexpected news. However, I believe these stocks below have some pretty amazing setups and with that reason alone it should be able to minimize my losses even when the market gaps down hard tomorrow. Anyway, here are the charts for all my overnight positions from Friday. Play it safe everyone.

Overnight positions $CHP $CUR $CYCC $KFS $PAL

PAL


KFS


CYCC


CUR


CHP